Table 1.
Selected population IPD and CAP disease burden estimates for PCV13 serotype CAP
Study | Population | Year | Incidence/100,000 |
---|---|---|---|
Waight et al [21] | England and Wales IPD – all ages |
2013/14 | 1.40 |
Waight et al [21] | England and Wales IPD- age >65 years |
2013/14 | 3.72 |
Rodrigo et al [29] | Nottingham (multicentre) CAP- adults all ages |
2012/13 | 8.60 |
Rodrigo et al [29] | Nottingham (multicentre) CAP- Age >65 years |
2012/13 | 16.75 |
Van Hoek et al [39] | England Risk groupsa Adult |
2008/9 | 37.10b |
Van Hoek et al [39] | England Risk groupsa ≥65 years |
2008/9 | 39.84b |
CAP refers to non-invasive and invasive pneumococcal community acquired pneumonia
arisk groups include asplenia/splenic dysfunction/chronic respiratory disease/chronic heart disease/chronic kidney disease/chronic liver disease/diabetes/immunosuppression/cochlear implants/cerebrospinal fluid leaks [39]
bdata extracted based on reported 83 % coverage of total IPD incidence by PCV13 during 2008/9